MiniMed Group (NASDAQ:MMED) Earns Buy Rating from Analysts at UBS Group

UBS Group began coverage on shares of MiniMed Group (NASDAQ:MMED) in a report published on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $25.00 price objective on the stock.

A number of other equities analysts have also issued reports on MMED. Wells Fargo & Company reduced their target price on MiniMed Group from $26.00 to $22.00 and set an “overweight” rating for the company in a research note on Thursday, June 4th. Evercore began coverage on MiniMed Group in a research note on Tuesday, March 31st. They set an “outperform” rating and a $20.00 price target on the stock. BTIG Research initiated coverage on MiniMed Group in a report on Tuesday, March 31st. They issued a “buy” rating and a $25.00 price objective on the stock. Weiss Ratings upgraded MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 20th. Finally, Deutsche Bank Aktiengesellschaft began coverage on MiniMed Group in a research report on Tuesday, March 31st. They issued a “buy” rating and a $20.00 target price on the stock. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $21.62.

MiniMed Group Stock Down 1.4%

MMED stock opened at $18.15 on Tuesday. The firm has a market cap of $5.10 billion and a PE ratio of -26.69. MiniMed Group has a 52 week low of $10.65 and a 52 week high of $20.48. The stock has a 50 day moving average of $14.84.

MiniMed Group (NASDAQ:MMED) last issued its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The business had revenue of $837.00 million for the quarter. The business’s revenue for the quarter was up 15.6% on a year-over-year basis.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.